Tofacitinib: a new oral Janus kinase inhibitor for psoriasis

被引：1
|
作者：
Gimenez-Arnau, A. M. [1 ]
机构：
[1] Univ Autonoma Barcelona, Hosp del Mar, Dept Dermatol, IMIM, Barcelona, Spain
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2019年 / 180卷 / 01期
关键词：
HERPES-ZOSTER; EFFICACY; MODERATE; VACCINE;
D O I：
10.1111/bjd.17323
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：13 / 14
页数：2
相关论文
共 50 条
  • [21] Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
    Charles-Schoeman, Christina
    Wicker, Pierre
    Gonzalez-Gay, Miguel A.
    Boy, Mary
    Zuckerman, Andrea
    Soma, Koshika
    Geier, Jamie
    Kwok, Kenneth
    Riese, Richard
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 46 (03) : 261 - 271
  • [22] Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of Tofacitinib, a Janus Kinase Inhibitor, in Healthy Volunteers
    Krishnaswami, Sriram
    Boy, Mary
    Chow, Vincent
    Chan, Gary
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (02): : 83 - 88
  • [23] A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
    Sandborn, William J.
    Ghosh, Subrata
    Panes, Julian
    Vranic, Ivana
    Wang, Wenjin
    Niezychowski, Wojciech
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1485 - U366
  • [24] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Mariette, X.
    Curtis, J.
    Lee, E.
    Benda, B.
    Kaplan, I.
    Soma, K.
    Kwok, K.
    Geier, J.
    Wang, L.
    Riese, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 230 - 230
  • [25] Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
    Nash, Peter
    Coates, Laura C.
    Fleischmann, Roy
    Papp, Kim
    Gomez-Reino, Juan J.
    Kanik, Keith S.
    Wang, Cunshan
    Wu, Joseph
    Hendrikx, Thijs
    Ports, William C.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [26] INTEGRATED EFFICACY ANALYSIS OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Nash, P.
    Coates, L. C.
    Fleischmann, R.
    Papp, K. A.
    Gomez-Reino, J. J.
    Kanik, K. S.
    Wang, C.
    Wu, J.
    Hendrikx, T.
    Ports, W. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 951 - 952
  • [27] Tofacitinib: A New Oral Therapy for Psoriasis
    Azevedo, Alexandra
    Torres, Tiago
    CLINICAL DRUG INVESTIGATION, 2018, 38 (02) : 101 - 112
  • [28] Tofacitinib: A New Oral Therapy for Psoriasis
    Alexandra Azevedo
    Tiago Torres
    Clinical Drug Investigation, 2018, 38 : 101 - 112
  • [29] Janus Kinase Inhibitor Tofacitinib for Induction and Remission in ulcerative colitis
    Sandborn, W. J.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2017, 142 (14) : 1022 - 1023
  • [30] Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
    Hall, Stephen
    Nash, Peter
    Rischmueller, Maureen
    Bossingham, David
    Bird, Paul
    Cook, Nicola
    Witcombe, David
    Soma, Koshika
    Kwok, Kenneth
    Thirunavukkarasu, Krishan
    RHEUMATOLOGY AND THERAPY, 2018, 5 (02) : 383 - 401
12345